Pacific Edge Draft LCD Proposes Medicare Coverage for Cxbladder Triage Tests

Medicare Draft LCD Marks First Coverage for Hematuria Evaluation

Pacific Edge (NZX/ASX:PEB) has taken a significant step towards US Medicare reimbursement with the publication of a draft Local Coverage Determination (LCD) that proposes coverage for its urine-based Cxbladder Triage and Triage Plus tests. This draft, titled 'Urine-based Biomarkers in Patients with Microhematuria' (DL40378), would establish hematuria evaluation as a covered Medicare benefit for the first time, distinguishing microhematuria patients as eligible for these specific biomarker tests.

The draft LCD explicitly includes only Cxbladder Triage and Triage Plus in its associated Local Coverage Article for billing and coding guidance, effectively creating a protective moat around Pacific Edge’s microhematuria diagnostics business. This exclusivity contrasts with the existing non-coverage LCD that applies to patients with cancer or strong suspicion of cancer, highlighting a narrower, clinically defined patient population for these tests.

Higher Reimbursement and Clinical Utility Drive Commercial Upside

Pacific Edge’s CEO Dr Peter Meintjes emphasised the commercial significance of the draft LCD, noting that Triage Plus is included with a Medicare price of US$1,328 per test, a 75% premium over the legacy Cxbladder products priced at US$760. This pricing shift could materially improve the company’s operating profitability in the US market, especially as Triage Plus offers broader clinical utility and cost benefits for healthcare systems.

The draft policy reflects the substantial clinical evidence Pacific Edge has generated, which was strongly endorsed by a Novitas-convened expert panel in February 2026. This panel’s recommendations and the alignment with American Urological Association guidelines underpin the policy’s rationale supporting limited coverage for urine-based biomarkers in a narrowly defined clinical context. The company’s focus on evidence-based value creation was highlighted as a core strength driving this milestone.

Pacific Edge’s progress follows earlier momentum, including growing Medicare policy support and commercial payer adoption across the US and Asia Pacific. The company reported a modest 2.7% increase in Q4 test volumes despite operational headwinds, reflecting sustained demand amid evolving reimbursement landscapes. This momentum builds on prior expert panel endorsements and strategic positioning efforts to regain Medicare coverage, which had been lost previously, impacting revenues and profitability Q4 2026 test volumes increased and Expert Panel Backs Medicare Coverage.

Regulatory Process and Market Implications

The draft LCD initiates a minimum 45-day public comment period during which Novitas will hold a meeting and accept submissions. Novitas must then respond to comments and publish a final LCD or withdraw the draft within 12 months. If finalised, the LCD will become effective 45 days after publication. Pacific Edge plans to seek reimbursement on a claim-by-claim basis during this draft period, leveraging the clear distinction between microhematuria patients and cancer patients in the coverage language.

Beyond Medicare’s 66 million beneficiaries, the draft LCD’s clarity is expected to influence US commercial payers covering 223 million lives and potentially catalyse international adoption. The company’s global footprint, with CLIA-certified labs in New Zealand and the US, and established presence in markets including Australasia, Israel, Asia, and South America, positions it well to capitalise on this regulatory development.

Capital Raising Supports Growth Amid Regulatory Advances

Coinciding with the draft LCD announcement, Pacific Edge has launched a NZ$6 million retail offer to existing shareholders following a NZ$25.4 million placement completed earlier in May 2026. The retail offer allows eligible shareholders to apply for up to NZ$50,000 of new shares at NZ$0.17 each, the same price as the placement, reinforcing shareholder support as the company approaches this pivotal commercial inflection point.

These capital initiatives aim to underpin further evidence generation and commercial expansion, including the rollout of higher-value tests like Triage Plus and future product developments beyond bladder cancer diagnostics. The company’s strategic focus on generating robust clinical evidence and aligning with medical policy frameworks remains central to its value creation strategy.